Neurocrine Biosciences (NBIX) Competitors $143.26 +1.34 (+0.94%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends NBIX vs. ALNY, BIIB, UTHR, INCY, BMRN, EXAS, EXEL, RGEN, HALO, and MDGLShould you be buying Neurocrine Biosciences stock or one of its competitors? The main competitors of Neurocrine Biosciences include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Exelixis (EXEL), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Neurocrine Biosciences vs. Alnylam Pharmaceuticals Biogen United Therapeutics Incyte BioMarin Pharmaceutical Exact Sciences Exelixis Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Alnylam Pharmaceuticals (NASDAQ:ALNY) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, community ranking, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations. Which has better valuation & earnings, ALNY or NBIX? Neurocrine Biosciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$1.83B17.37-$440.24M-$2.62-94.00Neurocrine Biosciences$1.89B7.69$249.70M$3.7338.41 Does the media prefer ALNY or NBIX? In the previous week, Alnylam Pharmaceuticals had 19 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 30 mentions for Alnylam Pharmaceuticals and 11 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.79 beat Alnylam Pharmaceuticals' score of 0.70 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 10 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 4 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in ALNY or NBIX? 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 4.3% of Neurocrine Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts prefer ALNY or NBIX? Alnylam Pharmaceuticals presently has a consensus target price of $298.61, suggesting a potential upside of 21.25%. Neurocrine Biosciences has a consensus target price of $164.81, suggesting a potential upside of 15.04%. Given Alnylam Pharmaceuticals' higher possible upside, equities research analysts clearly believe Alnylam Pharmaceuticals is more favorable than Neurocrine Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 19 Buy rating(s) 0 Strong Buy rating(s) 2.72Neurocrine Biosciences 0 Sell rating(s) 5 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 2.83 Does the MarketBeat Community prefer ALNY or NBIX? Alnylam Pharmaceuticals received 122 more outperform votes than Neurocrine Biosciences when rated by MarketBeat users. However, 77.44% of users gave Neurocrine Biosciences an outperform vote while only 76.17% of users gave Alnylam Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAlnylam PharmaceuticalsOutperform Votes113876.17% Underperform Votes35623.83% Neurocrine BiosciencesOutperform Votes101677.44% Underperform Votes29622.56% Is ALNY or NBIX more profitable? Neurocrine Biosciences has a net margin of 17.21% compared to Alnylam Pharmaceuticals' net margin of -15.86%. Neurocrine Biosciences' return on equity of 15.68% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-15.86% N/A -8.38% Neurocrine Biosciences 17.21%15.68%11.38% Which has more risk & volatility, ALNY or NBIX? Alnylam Pharmaceuticals has a beta of 0.34, indicating that its share price is 66% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. SummaryNeurocrine Biosciences beats Alnylam Pharmaceuticals on 12 of the 19 factors compared between the two stocks. Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBIX vs. The Competition Export to ExcelMetricNeurocrine BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.51B$2.96B$5.36B$9.13BDividend YieldN/A1.94%5.13%4.03%P/E Ratio38.4145.5689.4717.33Price / Sales7.69384.461,261.53136.12Price / Cash54.63192.9043.7535.97Price / Book6.313.975.324.80Net Income$249.70M-$41.02M$122.60M$224.91M7 Day Performance1.67%7.15%0.69%1.77%1 Month Performance4.81%5.53%1.55%2.22%1 Year Performance4.48%4.90%27.25%20.67% Neurocrine Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBIXNeurocrine Biosciences4.8842 of 5 stars$143.26+0.9%$164.81+15.0%+4.5%$14.27B$1.89B38.411,400Insider TradeNews CoverageALNYAlnylam Pharmaceuticals4.3797 of 5 stars$258.04+8.4%$298.61+15.7%+30.6%$33.28B$2.09B-98.492,100Analyst RevisionNews CoverageBIIBBiogen4.7146 of 5 stars$149.46+0.4%$230.00+53.9%-42.7%$21.78B$9.61B13.508,720Short Interest ↑UTHRUnited Therapeutics4.9234 of 5 stars$363.80-0.3%$378.36+4.0%+61.5%$16.24B$2.76B15.98980Analyst UpgradeInsider TradeShort Interest ↓Positive NewsINCYIncyte4.7449 of 5 stars$72.44+2.7%$76.29+5.3%+17.0%$13.96B$4.08B517.472,524Analyst ForecastShort Interest ↓News CoverageBMRNBioMarin Pharmaceutical4.9993 of 5 stars$66.68-1.0%$94.20+41.3%-34.1%$12.71B$2.75B39.933,401Options VolumeNews CoverageEXASExact Sciences4.764 of 5 stars$57.53+1.8%$72.94+26.8%-19.2%$10.65B$2.69B-49.176,600News CoverageGap UpEXELExelixis4.538 of 5 stars$35.24-2.2%$33.75-4.2%+60.6%$10.06B$2.08B22.591,310Analyst ForecastShort Interest ↑Analyst RevisionNews CoverageRGENRepligen3.7388 of 5 stars$157.28+1.6%$185.20+17.8%-6.0%$8.81B$639.92M-425.072,020HALOHalozyme Therapeutics4.5952 of 5 stars$54.06+2.4%$60.89+12.6%+52.1%$6.88B$947.36M17.90390Short Interest ↑Analyst RevisionMDGLMadrigal Pharmaceuticals4.557 of 5 stars$299.41-11.7%$350.83+17.2%+22.4%$6.53B$76.81M-11.9490Analyst ForecastInsider TradeAnalyst RevisionNews CoverageHigh Trading Volume Related Companies and Tools Related Companies Alnylam Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors Incyte Competitors BioMarin Pharmaceutical Competitors Exact Sciences Competitors Exelixis Competitors Repligen Competitors Halozyme Therapeutics Competitors Madrigal Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NBIX) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
